Showing 3 posts of 3 posts found.


GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …


New PARP inhibitor hits UK market, offering distinct advantage

December 18, 2017
Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …


Tesaro secures EU approval in specific ovarian cancer population

November 23, 2017
Sales and Marketing Europe, European Commission, Tesaro, Zejula, pharma

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.  Zejula is a poly (ADP-ribose) …

Latest content